

EXHIBIT A

Kathryn Allen

From: "Davidson, Kelly" <kjdavidson@ober.com>
To: <jcicala@kmlp.com>; <kbale@kmlp.com>
Cc: "Whitman, M. Hamilton Jr." <mhwhitman@ober.com>
Sent: Friday, May 16, 2008 5:12 PM
Attach: FUL_AMP_Information_(Wyeth_NY_Counties).XLS
Subject: Wyeth AMP Production

Dear Joanne and Kathryn,

Attached in Excel format is a spreadsheet containing the available AMP data from January 1, 1997, up through and including December 31, 2005, for the NDCs listed in my letter to Joanne dated March 5, 2008. We have Bates-stamped the entire spreadsheet as WYNY 0005674. A fourth production of documents from the files of Richard Truex was sent to your attention today as WYNY 0004674-0005673, which accounts for the apparent gap in bates numbering between Wyeth's third document production and the attached AMP spreadsheet.

Please note that the attached spreadsheet has been marked "Highly Confidential." We ask that it be treated in accordance with paragraph 4 of the Protective Order that governs this action.

Regards,

Kelly

<<FUL_AMP_Information_(Wyeth_NY_Counties).XLS>>

Kelly J. Davidson

kjdavidson@ober.com

410-347-7395 -- Direct Dial

443-263-7595 -- Direct Fax

410-547-0699 -- General Fax

OBER|KALER

Attorneys at Law

www.ober.com

120 East Baltimore Street

Baltimore, Maryland 21202

EXHIBIT B

30(b)(6) Wyeth (Truex, Ph.D., Richard)

June 19, 2008

1

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY MDL No. 1456
AVERAGE WHOLESALE PRICE :Master File No.
LITIGATION :01-12257-PBS
:
THIS DOCUMENT RELATES TO: :
CITY OF NEW YORK, et al., :
v. :
ABBOTT LABORATORIES, et al. :

Thursday, June 19, 2008

Videotaped 30(b)(6) examination of
WYETH (RICHARD TRUEX, Ph.D.), held in the offices
of Reed Smith, 2500 One Liberty Place, 1650 Market
Street, Philadelphia, PA 19103, commencing
at 10:14 a.m., on the above date, before
Mickey Dinter, Registered Professional Reporter and
Notary Public for the Commonwealth of Pennsylvania.

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

30(b)(6) Wyeth (Truex, Ph.D., Richard)

June 19, 2008

7 (Pages 22 to 25)

<p style="text-align: right;">22</p> <p>1 Q. Because, as you testified already, I</p> <p>2 believe different people set the prices on the</p> <p>3 generic side and reported them, correct?</p> <p>4 A. That's correct.</p> <p>5 Q. Did you have any responsibility for</p> <p>6 reporting Lorazepam prices to the pricing compendia</p> <p>7 in the position you held when you first joined</p> <p>8 Wyeth?</p> <p>9 A. No.</p> <p>10 Q. Is it fair to say your price reporting</p> <p>11 responsibilities began in 1999?</p> <p>12 A. That's correct.</p> <p>13 Q. Did you continue to have price reporting</p> <p>14 responsibilities for Lorazepam when you became</p> <p>15 executive director of U.S. pricing?</p> <p>16 A. I did.</p> <p>17 Q. By you, I assume, it was someone who</p> <p>18 reported to you?</p> <p>19 A. That's correct. It wasn't me personally.</p> <p>20 Q. You and I are going to have to try not to</p> <p>21 talk on top of each other. We are both doing it,</p> <p>22 so I will try to not cut you off and, please, try</p>	<p style="text-align: right;">24</p> <p>1 committee. The pricing committee was not involved</p> <p>2 in setting prices for Ativan.</p> <p>3 Q. Thank you.</p> <p>4 (Exhibit Truex 001, a Revised 30(b)(6)</p> <p>5 Notice of Deposition of Wyeth, marked for</p> <p>6 identification.)</p> <p>7 BY MS. CICALA:</p> <p>8 Q. Dr. Truex, we have marked as Exhibit</p> <p>9 Number 1, the Revised 30(b)(6) Notice of Deposition</p> <p>10 of Wyeth that my client served in this case. Have</p> <p>11 you seen this particular document before?</p> <p>12 A. Yes, I have.</p> <p>13 Q. Is this the document you were referring to</p> <p>14 when you made reference to a list of questions that</p> <p>15 you were to address?</p> <p>16 A. Yes.</p> <p>17 Q. You understand that you have been</p> <p>18 designated by Wyeth to testify on behalf of the</p> <p>19 company on certain of the topics listed in Exhibit</p> <p>20 1, is that correct?</p> <p>21 A. I understand that.</p> <p>22 Q. Your counsel has informed me that you have</p>
<p style="text-align: right;">23</p> <p>1 to let me finish my question just so our record is</p> <p>2 clear.</p> <p>3 A. Sure, absolutely.</p> <p>4 Q. Thank you.</p> <p>5 A. You're welcome.</p> <p>6 Q. As senior director of U.S. pricing, did</p> <p>7 you also have responsibility for price reporting</p> <p>8 for Ativan?</p> <p>9 A. Yes.</p> <p>10 Q. And did you continue to have price</p> <p>11 reporting responsibilities for Ativan when you</p> <p>12 became executive director of U.S. pricing?</p> <p>13 A. Yes.</p> <p>14 Q. But in your capacity of executive director</p> <p>15 of U.S. pricing and in the context of Ativan, you</p> <p>16 would also be involved in setting the prices for</p> <p>17 Ativan, is that correct?</p> <p>18 A. That's correct.</p> <p>19 Q. Did you participate in the pricing</p> <p>20 committee in connection with setting prices for</p> <p>21 Ativan?</p> <p>22 A. I participated in a, in the pricing</p>	<p style="text-align: right;">25</p> <p>1 been designated to testify on topics number 24</p> <p>2 through 31. Is that your understanding? Please</p> <p>3 take a --</p> <p>4 A. I didn't focus on the numbers. I was</p> <p>5 supposed to testify. I'm fine with that.</p> <p>6 Q. Okay. Could you, please, review the</p> <p>7 topics, 24 through 31, and then let me know if you</p> <p>8 understand that you are here to address the subject</p> <p>9 matters that are described in those topics?</p> <p>10 A. Yes.</p> <p>11 Q. And your counsel has also indicated that</p> <p>12 you will be, you are here to testify with regard to</p> <p>13 subjects 33, 34 and 35. Could you, please, review</p> <p>14 those and confirm for me that you have the same</p> <p>15 understanding.</p> <p>16 A. I do.</p> <p>17 Q. Okay. Can you describe for me who,</p> <p>18 between the years 1997 through 2005, who was</p> <p>19 responsible for determining the prices that Wyeth</p> <p>20 would report to the publishing compendia for</p> <p>21 Lorazepam?</p> <p>22 A. Who was responsible for establishing the</p>